MATN Mateon Therapeutics Inc.

MATEON ANNOUNCES FIRST PATIENT ENROLLED IN ARTI-19: A MULTICENTER INTERVENTIONAL STUDY OF ARTISHIELD™ AGAINST COVID-19

MATEON ANNOUNCES FIRST PATIENT ENROLLED IN ARTI-19: A MULTICENTER INTERVENTIONAL STUDY OF ARTISHIELD™ AGAINST COVID-19
EN
07/10/2020

Underlying

MATNMateon Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Mateon Therapeutics Inc.

 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic Therapeutics Details PDAOAI Platform and Opens Access to Its...

Oncotelic Therapeutics Details PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus AGOURA HILLS, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today opened access to PDAOAI, its proprietary evidence-interrogation platform designed to extract biologically meaningful signals from large, complex biomedical datasets without training bespoke large language models (LLMs) on proprietary data. The Company is also providing researchers access to a TGF-...

December 22, 2025 1 EN
 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic Therapeutics and Brush and Key Foundation Announce Publicati...

Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer AGOURA HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) in collaboration with the Brush and Key Foundation, today announced the publication of a peer-reviewed research article in the International Journal of Molecular Sciences titled “Comparative Tumor Microenvironment Analysis for HCC and PDAC Using KMplotter.” Chang, W.-H.; Shah, D.; Myers, S.; Potts, M.;...

December 15, 2025 1 EN
 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framewor...

Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine AGOURA HILLS, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano today announced new biomarker data identifying a molecular signature that predicts sensitivity to Sapu003, the company’s intravenous Deciparticle™ formulation of everolimus. These data will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) Dec 9-12. This work describes the ...

December 4, 2025 1 EN
 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003...

Oncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing AGOURA HILLS, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano today announced new pharmacokinetic (PK) and tissue-distribution results demonstrating that Sapu003, the company’s intravenous (IV) Deciparticle™ formulation of everolimus, substantially reduces gastrointestinal (GI) drug accumulation, addressing one of the most significant and well-recognized limitations of or...

December 3, 2025 1 EN
 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nano...

Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs AGOURA HILLS, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano, a clinical-stage nanomedicine company, today announced new data demonstrating that its proprietary Deciparticle™ platform enables broad and consistent formulation of structurally diverse hydrophobic therapeutics—including macrolide mTOR inhibitors, cyclic peptides, linear peptides, asco...

December 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch